Directorio

In this study, researchers will ask people to answer surveys over time. The surveys ask about daily life after transplant, whether they still have help from caregivers after the first few months, and if their workplace offers support or changes to help them return to work. The surveys also ask about money worries, job plans, and decisions about going back to work after the transplant.

This program lasts four to eight weeks and is designed to help people get ready to return to work after a transplant. At the first visit, an occupational therapist will do a long evaluation that may take two to four hours. During this time, the person will do activities that copy real work tasks, such as lifting, carrying, pushing, pulling, and staying active for a long time. This helps measure strength, energy, and ability to handle work duties safely. The program also includes checks of physical health, thinking skills, and mental health. The team will talk with the person about their home support, motivation to return to work, past abilities, and previous job tasks. When needed, the team will also talk with employers about job duties and possible changes to make returning to work safer and easier.

People in this study will take part for about one year. At the beginning, they will be placed into one of three groups by chance, like flipping a coin. One group will take two study medicines together. Another group will take one study medicine by itself. The third group will take a placebo, which looks like medicine but has no active drug. For the first twelve weeks, neither the participants nor the study team will know which pills are taken. During this time, people will take pills once a day, come to study visits, and have blood tests and health checks. After the first twelve weeks, everyone will take the two study medicines together for nine more months, with regular clinic visits and tests to check cholesterol levels and safety.

We are doing this study to find out if either of 2 different, experimental drug regimens (ramucirumab plus paclitaxel or FOLFIRI) is an option for treating small bowel cancer that has not responded to therapy.

We are doing this study to compare the early treatment (before you have cancer symptoms) of Venetoclax and Obitnutuzumab (V-O) to the usual treatment of V-O after you have cancer symptoms. This study will help doctors figure out if early treatment is better, the same, or worse than the usual approach of waiting until the patient has cancer symptoms before starting treatment.

We are doing this study to compare the usual treatment for neuroendocrine carcinomas to using atezolizumab plus the usual treatment. Another purpose is to compare using atezolizumab just at the beginning of treatment to continuing it beyond the initial treatment.

In this study, people go through a screening period and testing to learn more about their cancer. Based on special features of the cancer, called biomarkers, they are placed into one of three groups. In each group, people are also placed by chance into one of two treatment options. In all groups, one option is to receive a medicine called durvalumab. The other option is to receive durvalumab together with another medicine. The extra medicine depends on the group and may be saruparib, ceralasertib, or monalizumab. The goal of the study is to see which treatment works best for different types of cancer based on their specific features.

In this study, people will be randomly placed into one of two groups, like flipping a coin. One group will take a new medicine called safusidenib, and the other group will take a fake pill called a placebo. They will take the pills twice a day in 28-day cycles. Doctors will check their health and the size of their brain tumor with regular MRI scans, blood tests, and check-ups. People will also answer questions about how they feel. The study will keep going until the tumor grows or there is another reason to stop.